Abivax SA
PAR:ABVX
Abivax SA
PP&E Net
Abivax SA
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Abivax SA
PAR:ABVX
|
PP&E Net
€2.2m
|
CAGR 3-Years
178%
|
CAGR 5-Years
85%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
PP&E Net
€142.1m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
13%
|
CAGR 10-Years
13%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
PP&E Net
€7.9m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
19%
|
|
|
Inventiva SA
PAR:IVA
|
PP&E Net
€4m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
PP&E Net
$16.6m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
22%
|
|
|
Sensorion SA
PAR:ALSEN
|
PP&E Net
€2.4m
|
CAGR 3-Years
13%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
Abivax SA
Glance View
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
See Also
What is Abivax SA's PP&E Net?
PP&E Net
2.2m
EUR
Based on the financial report for Jun 30, 2025, Abivax SA's PP&E Net amounts to 2.2m EUR.
What is Abivax SA's PP&E Net growth rate?
PP&E Net CAGR 5Y
85%
Over the last year, the PP&E Net growth was -16%. The average annual PP&E Net growth rates for Abivax SA have been 178% over the past three years , 85% over the past five years .
